Répertoire du corps professoral

Investigation of neuroprotective and neurorescue properties of zuranolone in a mouse model of Parkinson’s disease
Programme: Programme de projets pilotes
Organisme(s) subventionnaire(s): Parkinson Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 août 2024 au 31 juillet 2025

Mechanisms of action of sex-specific endocrine treatments in complementary models of Parkinson's disease
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2024 au 31 mars 2029

Brain magnetic stimulation to reduce levodopa-induced dyskinesias in Parkinson’s disease
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2024 au 31 mars 2026

Financements des 2 dernières années

Mechanisms of action of sex-specific endocrine treatments in animal models of Parkinson's disease
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 mars 2023 au 29 février 2024

Relationship between COVID-19 and Parkinson’s disease in a mouse model
Programme: Programme de projets pilotes
Organisme(s) subventionnaire(s): Parkinson Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2022 au 31 mars 2024

Pregnenolone for the treatment of dyskinesia in Parkinson’s disease
Organisme(s) subventionnaire(s): Michael J. Fox Foundation for Parkinson's Research
Type de financement: Subvention
Établissement tête: Università Degli Studi Di Cagliari
Du 1 avril 2022 au 1 septembre 2024

Sex-specific investigations of Parkinson's disease mouse models: application for gonadal drugs repurposing
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2018 au 31 mars 2023

Encadrements terminés dans les 5 dernières années

Estelle Gouriou, Doctorat en neurosciences

Amandine Isenbrandt, Maîtrise en sciences pharmaceutiques - avec mémoire

Publications des 5 dernières années

Exploring Magnetic and Electrical Brain Stimulation in Parkinsonian Dyskinetic Monkeys Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2024/11/12. Estelle Gouriou, Mélanie Bourque, Cyril Schneider, Thérèse Di Paolo. DOI 10.1017/cjn.2024.284

Sex and Age Differences in a Progressive Synucleinopathy Mouse Model Biomolecules, 2023/06/11. Jérôme Lamontagne-Proulx, Katherine Coulombe, Marc Morissette, Marie Rieux, Frédéric Calon, Thérèse Di Paolo, Denis Soulet. DOI 10.3390/biom13060977

Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys Cells, 2022. DOI 10.3390/cells11040691

Peripheral Neuroprotective and Immunomodulatory Effects of 5α-Reductase Inhibitors in Parkinson’s Disease Models Frontiers in Pharmacology, 2022. Poirier, A.-A., Côté, M., Jarras, H., Litim, N., Lamontagne-Proulx, J., Al-Sweidi, S., Morissette, M., Lachhab, A., Pelletier, M., Di Paolo, T., Soulet, D.. DOI 10.3389/fphar.2022.898067

Neuroactive steroids and Parkinson's disease Current opinion in endocrine and metabolic research., 2022. DOI 10.1016/j.coemr.2021.100312

Liquid chromatography coupled to tandem mass spectrometry methods for the selective and sensitive determination of 24S-hydroxycholesterol, its sulfate, and/or glucuronide conjugates in plasma Journal of mass spectrometry : JMS, 2022. DOI 10.1002/jms.4827

AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys Cells, 2022. Bourque, M., Grégoire, L., Patel, W., Dickens, D., Snodgrass, R., Di Paolo, T.. DOI 10.3390/cells11223530

Microglial Implications in SARS-CoV-2 Infection and COVID-19: Lessons From Viral RNA Neurotropism and Possible Relevance to Parkinson's Disease Frontiers in cellular neuroscience, 2021. DOI 10.3389/fncel.2021.670298

Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice Neuropharmacology, 2021. DOI 10.1016/j.neuropharm.2021.108784

Androgens and Parkinson's Disease: A Review of Human Studies and Animal Models Androgens: clinical research and therapeutics, 2021. DOI 10.1089/andro.2021.0011

Remodeling microglia to a protective phenotype in Parkinson's disease? Neuroscience letters, 2020. DOI 10.1016/j.neulet.2020.135164

Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson's disease Journal of neuroendocrinology, 2020. DOI 10.1111/jne.12782

Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinson's disease Brain, behavior, and immunity, 2020. DOI 10.1016/j.bbi.2020.07.044

Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease Neuropharmacology, 2019. DOI 10.1016/j.neuropharm.2018.04.005

Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor Brain research, 2019. DOI 10.1016/j.brainres.2019.146460

Drug repurposing: Old drugs, new tricks to fast track drug development for the brain Neuropharmacology, 2019. DOI 10.1016/j.neuropharm.2019.01.009